Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate Cancer
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Jason R. Williams, MD, DABR, spoke with CancerNetwork® about ongoing efforts to research how ablative techniques can be combined with intra-tumoral immunotherapy to improve outcomes in patients with solid tumors.
Specifically, Williams, a board-certified radiologist, and president and director of interventional oncology and immunotherapy at Williams Cancer Institute, highlighted the ongoing phase 1b LEGION-100 trial (NCT06533644) assessing the multi-target immunotherapy SYNC-T SV-102 among patients with metastatic castration-resistant prostate cancer (CRPC). According to Williams, prior data show that ablative technology can generate an immune response in patients, which can be enhanced with the use of injectable immunotherapy agents.
Developers designed SYNC-T to activate T cells and stimulate the immune system as part of treating patients with metastatic solid tumors. The modality combines in situ vaccination via device-induced partial oncolysis and intra-tumoral infusion of a multi-target drug, which may synchronize the timing and location of tumor antigen release when immune cells activate.
The FDA cleared an investigational new drug application for SYNC-T SV-102 for those with metastatic CRPC in May 2024. Prior phase 1 data showed that the treatment produced an objective response rate of 85% among 13 evaluable patients, which included complete responses in 5 and partial responses in 6. Additionally, complete resolution of bone metastases occurred in 54% of patients. Investigators reported that the treatment was well tolerated and yielded no significant safety concerns.
Transcript:
We have our clinical trial with Syncromune; it is the LEGION-100 trial. That’s for prostate cancer; [we are] doing cryolysis with an injection of immunotherapy. I don’t know if there are any others that are doing the same type of thing. There’s been a lot of people who looked at these things where you could do ablation and inject immunotherapy simultaneously. There’s been other studies as well.
That trial showed an [85%] objective response rate in castration-resistant prostate cancer. These are patients with stage [disease]. That’s significant. We’re seeing the ablative technology generates an immune response, and we can enhance it by injecting the drugs in there with it as well.
Reference
Syncromune® Inc. announces FDA clearance of IND application for SYNC-T SV-102, a first-in-class combination multi-target immunotherapy for metastatic castrate-resistant prostate cancer. News release. Syncromune, Inc. May 30, 2024. Accessed November 25, 2024. https://tinyurl.com/5e8kw3ys
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
